Pharmaceutical intermediates Clofarabine raw powder

CAS:123318-82-1

MF:C10H11ClFN5O3

MW:303.68

EINECS:631-422-9

Specification​: 99% min Clofarabine

Sample:Clofarabine

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Clofarabine Usage and Synthesis.

clofarabine, also known as clofarabine, is a new purine nucleoside anticancer drug, successfully developed by GenzymeCorporation (GenzymeCorporation, NASDAQ:GENZ), a top ten biopharmaceutical company in the United States, and its trade name is Clofarabine. On December 28, 2004, the United States Food and Drug Administration (FDA) approved clofarabine for the treatment of intractable or recurrent acute lymphoblastic leukemia in children through the fast track, which is the only drug that can be used specifically for the treatment of acute myeloid leukemia (ALL) in children. The treatment of leukemia is highly effective and well tolerated, with no unpredictable adverse reactions. It can be administered intravenously or orally, making it the first new leukemia treatment approved specifically for children in more than a decade.

.

Uses of Clofarabine.

Pharmacological action of Clofarabine.

Clorabine combines the advantages of Fludarabine and Cladribine to inhibit both DNA polymerase and ribonucleic acid reductase. It showed strong anticancer activity against different cell lines and tumor models. Early studies have shown that the concentration of this product below micromole can effectively inhibit the proliferation of human CNS tumors, lung cancer, kidney cancer, leukemia cells and melanoma cell lines. In vivo and in vitro experiments have shown that Crorolabine has apoptotic effect on leukemia cells. This effect is achieved by down-regulating the dephosphorization of BCL-2 group proteins BCL-X and MCL-1 and AKT. Its inhibitory effect on human leukemia cells K-562 was stronger than that of latabine and fludatrebine, with IC50 of 5nmol/L, while the IC50 of clatrebine was 16nmol/L and that of Fludatrebine was 460nmol/L. Preclinical and combination trials have shown that clofarabine and other deoxynucleotide analogues, as well as other types of anticancer agents such as etoposide, can increase the activity of deoxycytidine kinase in normal or abnormal human lymphocytes and therefore increase the anticancer efficacy.

Product Method of Bulk Clofarabine.